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Since the term "lymphokine" first appeared in print over 
20 years ago, a tremendous number of these soluble 
mediators of the immune system have been described. 
Within the past few years, many human nonspecific 
suppressive lymphokines have been identified. This re- 
view discusses the historical basis of immunologic sup- 
pression and suppressor factors. Later reports describing 
suppressive human lymphokines are then grouped into 
four categories: primarily stimulatory lymphokines that 
also mediate certain suppressive activities, suppressive 
lymphokines produced during altered states of immunity, 
suppressive Iymphokines produced by exogenously stim- 
ulated lymphocytes, and suppressive lymphokines pro- 
duced by unstimulated lymphocytes. Recent work I have 
been involved in focusing on the human suppressive 
lymphokine soluble suppressor factor (SSF) is also dis- 
cussed. 
KEY WORDS: Immunosuppression; lymphokines; suppressive 
factors; review. 
INTRODUCTION 
Over the past few years, there has been a tremen- 
dous increase in the number of identified human 
lymphokines. A majority of these lymphokines 
have been stimulatory or helper factors. However, 
a large number of suppressive lymphokines have 
also recently been described. This review examines 
the historical basis of immunologic suppression and 
suppressor factors and then discusses a number of 
different types of suppressive lymphokines. The 
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review concludes by discussing recent work with 
the lymphokine soluble suppressor factor (SSF). 
HISTORICAL BACKGROUND OF IMMUNOLOGIC 
SUPPRESSION 
The term "lymphokines" was first used by Du- 
monde et al. approximately 20 years ago (1). Lym- 
phokines were defined as "cell-free soluble factors, 
which are generated during interaction of sensitized 
lymphocytes with specific antigens." Lymphokines 
were further differentiated from antibodies as being 
"expressed without reference to immunological 
specificity." Dumonde et  al. demonstrated four 
functions of lymphocyte-produced soluble factors 
in a guinea pig model: induction of intradermal 
inflammation, transformation of lymphocytes, cyto- 
pathic action on fibroblast monolayers in culture, 
and inhibition of migration of peritoneal macro- 
phages. 
The cellular basis of suppression of the immune 
system was also first demonstrated approximately 
20 years ago, by Gershon and Kondo (2). In these 
classic experiments, adult mice were made tolerant 
to sheep red blood cells (SRBC). Cells from these 
tolerant mice could be transferred to naive mice 
(mice not previously exposed to SRBC), and these 
recipient mice would then also be tolerant to SRBC. 
This induction of tolerance was shown to be medi- 
ated by the transfer o fa  Lyt 2,3 + T-cell subset, later 
known as T-suppressor cells (Ts). Gershon et  ai. 
later showed that Ts cells are capable of suppressing 
immunologic responses by other T cells without the 
aid of B cells or antibodies (3). 
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Merging of the concepts of lymphokines and 
immunologic suppression was first seen in studies 
by various investigators including Tada, Benacer- 
raf, and others on antigen-specific suppressive lym- 
phokines. Ts cells were collected from mice that did 
not respond to or had been made tolerant to a 
specific antigen, such as keyhole limpet hemocya- 
nin (KLH) or L-glutamine-L-alanine-L-tyrosine 
(GAT). Cell-free extracts from these T s cells were 
prepared by sonication, and these extracts were 
injected into mice that would normally respond to 
the specific antigen. These recipient mice then 
showed decreased immune responses to the specific 
antigen (4). 
These suppressive factors, called TsF, are 
thought to be products of Ts-cell subsets stimulated 
by their specific antigen. All share a number of 
biochemical properties, including being proteins 
with molecular weights between 35 and 60 kD, 
specifically binding the antigen used to stimulate Ts 
cells to make this factor, and bearing determinants 
coded by a component of the mouse MHC class II 
region (H-2) called the I-J region, and acting only in 
mice strains syngeneic to the strain which produced 
the factor (4, 5). It has also been reported that the 
target of TsF is the Lyt 1,2,3 + I-J + T-cell subset. 
T~F causes the latter cells to become active Ts cells 
(4-6). 
Later research has indicated that there are at 
least two and possibly three or more levels of 
antigen-specific Ts cells and T~-cell factors operat- 
ing in a complex network of regulation. Initially, it 
was proposed that antigen stimulated a cyclophos- 
phamide-sensitive class of Ts cells designated Tsl 
(5, 6). These cells produce a factor, TsFv This 
factor is a single-chain polypeptide containing an 
antigen-binding site and MHC-encoded determi- 
nants and is not genetically restricted to syngeneic 
strains. TsF 1 activates a second class of T-suppres- 
sor cells, the cyclophosphamide-resistant Ts2 cells. 
T~z cells then produce a second factor, TsF2, which 
consists of two-polypeptide chains linked by a di- 
sulfide bond. One of the chains bears an MHC- 
encoded determinant; the other appears to contain 
either an antigen-binding site or an idiotype-specific 
site. This factor is genetically restricted to function 
only in syngeneic mice. T~F2 may then stimulate 
one of more other sets of T-suppressor cells (Ts3) 
resulting in suppression of specific effector func- 
tions (5, 6). For example, T~F2 may stimulate the 
so-called auxiliary cells which function to suppress 
contact sensitivity. These cells could then produce 
a third suppressor factor (TsF3), which would actu- 
ally mediate immunologic suppression (7). 
These various putative T-suppressor factors have 
yet to be isolated or purified. However, their exis- 
tence has been called into doubt by difficulties in 
locating the I-J locus in the murine MHC. Numer- 
ous reports have indicated that at least some of 
these factors interact with antisera to determinants 
coded for by the K end of the mouse H-2 region (8). 
These determinants, as discussed above, were des- 
ignated I-J. Reports map the I-J locus "unambig- 
uously" to the mouse MHC (9). However, molec- 
ular mapping of the mouse MHC indicates that the 
two regions surrounding the I-J region (the I-A and 
I-E regions) are separated by no more than 3.4 kb 
and may be separated by less than 1 kb or may even 
be continuous (10). Thus, it is difficult to envision at 
least one and possibly two (I-J and I-B) polymor- 
phic regions within such a short span of DNA. If the 
I-J region does exist, other possible locations in- 
clude existing outside of the murine I region; having 
identity with Ebeta or a fragment of Ebeta but dif- 
fering in posttranslational modification and/or con- 
formation; and being produced from differential 
RNA splicing of a polymorphic RNA encoded by 
I-A, I-E, or a region between I-A and I-E (t0). 
SUPPRESSIVE ACTIVITIES OF PREDOMINANTLY 
STIMULATORY LYMPHOKINES 
While a large body of literature exists on antigen- 
specific suppressive lymphokines in mice, few stud- 
ies have been performed in humans on this type of 
factor (11, 12). Most corresponding studies in hu- 
mans have identified nonspecific suppressive lym- 
phokines. A number of reviews on this topic have 
been published (13-16). Nonspecific suppressive 
lymphokines fall into two broad classes: predomi- 
nantly stimulatory lymphokines which also have 
suppressive functions and lymphokines which ap- 
pear to be only suppressive. Interferon (IFN) 
gamma falls into this first class. IFN-gamma is a 
product of stimulated T and B cells. In humans, 
IFN-gamma has been shown to inhibit: lymphocyte 
proliferation to certain mitogens, antigens, and al- 
logeneic cells (17, 18); certain B-cell functions (19); 
and the mixed lymphocyte reaction (MLR) (17). 
Recombinant IFN-gamma has also been reported to 
induce a brief enhancement of IL-2-stimulated lym- 
phokine-activated killer (LAK) cells after 2 days of 
in vitro incubation followed by a pronounced inhi- 
bition of LAK activity after 6 days (20). IFN- 
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associated suppression may occur with IFN con- 
centrations as low as 10 U/ml (17). Johnson and 
Blalock (21) have shown that IFN can activate 
suppressor cells in mice that produce a soluble 
factor capable of suppressing plaque-forming cell 
(PFC) responses to SRBC. This suppressor factor 
may be similar or identical to a well-known suppres- 
sor factor, the soluble immune response suppressor 
(SIRS) (discussed below). 
Another predominantly stimulatory factor with 
suppressive actions is the family of transforming 
growth factors ffGF). These peptides can induce 
nonneoplastic cells to express transformed pheno- 
types. The most thoroughly characterized factor of 
this family is TGF-beta. TGF-beta is a 25-kD ho- 
modimer produced by a number of cell types and 
capable of suppressing B- and T-cell proliferation 
and NK-cell cytotoxicity (22). Other suppressive 
effects of TGF-beta include inhibition of IL-I- 
induced lymphocyte proliferation. This suppression 
is not due to a direct IL-1 inhibitor, as discussed[ 
below, as the suppression occurs distal to the IL-1 
receptor (23). 
The mechanism of TGF-beta-mediated suppres-. 
sion is uncertain. TGF-beta does not suppress aug- 
mentation of NK cytotoxicity by exogenous IL-2 
but does suppress augmentation by exogenous IFN. 
This suggests that TGF-beta functions by inhibiting 
enhancement of NK cytotoxicity by endogenous 
IFN (22). However, TGF-beta can suppress IL-2-. 
driven LAK-cell proliferation and cytotoxicity in a 
dose-dependent manner at concentrations as low as 
5 ng/ml (24). It has also been proported that TGF- 
beta may exert suppressive activities by down- 
regulation of lymphocyte cell surface receptors 
(22). 
Other predominantly stimulatory factors that also 
have limited suppressive abilities include IL-6, 
which inhibits the growth of certain myeloid leuke- 
mic cells lines and breast carcinoma cell lines (25); 
IL-4, which inhibits IL-2 and lipopotysaccharide 
(LPS)-mediated stimulation of the production of 
certain immunoglobulins (26, 27); and connective 
tissue activating peptide I (CTAP-I), which can 
indirectly mediate immunosuppression by stimulat- 
ing production of prostaglandin E 2 (28). 
SUPPRESSIVE L Y M P H O K I N E S  PRODUCED IN 
STATES OF ALTERED IMMUNITY 
A number of lymphokines have been described as 
being produced primarily or solely in disease states 
or other states characterized by altered immune 
responses. Linker-Israeli and Casteel (29) have de- 
scribed factors produced by unstimulated periph- 
eral blood mononuclear cells (PBMC) from patients 
with systemic lupus erythematosus (SLE). These 
factors, termed SF PBM, suppressed production of 
IL-2 by PHA-stimulated PBMC from healthy sub- 
jects or SLE patients and IL-2 production by Jurkat 
cells, a constitutive IL-2-producing cell line. Both 
monocytes and CD8 + lymphocytes were necessary 
to produce this suppressive activity. SF PBM did 
not inhibit proliferation of IL-2-dependent or -inde- 
pendent cell lines and had no IFN activity. These 
factors are sensitive to acid (pH 2), 56°C, and 
trypsin. Two molecular weight ranges of SF PBM 
activity were detected by gel filtration, <150 kD 
(fraction II) and 40 to 60 kD (fraction IV). Fraction 
II mediated suppression in a manner similar to 
unseparated SF PBM, while fraction IV was active 
only when monocytes were present. This suggests 
that fraction IV requires monocyte processing for 
activity such as the suppressive lymphokine SIRS, 
discussed below; however, 2-mercaptoethanol, an 
inhibitor of SIRS activity, had no effect on either 
fraction. 
Pregnancy, while clearly not a disease state, is 
characterized by alterations in immunity. Nagaoki 
et al. (30) have shown that pokeweed mitogen 
(PWM)-stimulated cord blood T cells produce a 
dialyzable factor capable of suppressing the gener- 
ation of plasma cells by PWM stimulated adult 
peripheral blood lymphocytes (PBL). Cord non-T 
cells, adult T cells, or adult non-T cells were 
incapable of producing this suppressive factor. De- 
velopment of suppressive activity took at least 12 hr 
following PWM stimulation and was no longer pro- 
duced after 48 hr poststimulation. This factor, 
named cord T cell-derived suppressive factor 
(CTSF), is stable at 56°C for 30 min but is inacti- 
vated at by treatment at 80°C for I0 min (31). 
Production of CTSF activity was abrogated by 
irradiating cord T cells with 1000 rads (30). 
Williams and Korsmeyer (32) have studied sup- 
pression mediated by supernates from Con A-acti- 
vated lymphocytes in two other immunologically 
altered states. Supernates from a subset of healthy 
individuals were capable of suppressing the MLR. 
A greater proportion of supernates from cord blood 
samples or from subjects with common variable 
immunodeficiency showed suppression of the 
MLR. This suppressive activity was stable at 56°C 
but inactivated at 70°C. Suppressive activity was 
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disrupted by treatment at pH 2.0 or with chymot- 
rypsin but was resistant to neuraminidase, RNase, 
or DNase. This activity may be identical to other 
suppressive factors discussed herein, but definitive 
purification and characterization have not been re- 
ported. 
Several investigators have examined suppressive 
lymphokines produced in human immunodeficiency 
virus (HIV)-infected individuals. Laurence et  al. 
(33) have shown that supernates from cultured 
PBMC of patients with the acquired immune defi- 
ciency syndrome (AIDS) or its prodrome were 
capable of suppressing spontaneous and PWM- 
stimulated differentiation of B cells as well as anti- 
gen-mediated T-cell transformation, while no such 
suppressive activity was found in comparable su- 
pernates of healthy controls. These supernates did 
not affect T cell-independent immune responses. 
Suppressive activity was produced by the interac- 
tion of T cells with adherent cells. T cells from 
AIDS patients, but not from healthy controls, in 
collaboration with adherent cells from healthy con- 
trol individuals were also capable of producing this 
activity. This activity was reversed by 2-mercapto- 
ethanol, suggesting that the activity may be similar 
to the soluble immune response suppressor (SIRS), 
discussed below. 
Henderson et  al. (34) have examined a suppres- 
sive factor(s) produced by healthy individuals in 
response to ultraviolet-irradiated HIV (uv-HIV). 
Cultures of healthy PBMC exposed to uv-HIV in 
the presence of PHA produce supernates capable of 
suppressing PHA-induced proliferation in other 
PBMC cultures. Supernates from PBMC cultures 
either untreated or treated with only PHA did not 
mediate this suppression. Suppression was not due 
to the presence of the uv-irradiated HIV or residual 
HIV proteins. This suppressive activity is sensitive 
to heat (1 hr at 56°C) and trypsin. It was suggested 
that this immunosuppression may be due to killing 
of CD4 ÷ cells. 
SUPPRESSIVE LYMPHOKINES PRODUCED BY 
EXOGENOUSLY-STIMULATED LYMPHOCYTES 
A number of factors have been described that are 
produced by concanavalin A (Con A)- or pokeweed 
mitogen (PWM)-activated lymphocytes or lympho- 
cyte subsets. One of the first sets of Con A-acti- 
vated factors to be characterized is the family of 
migration inhibitory factors: fibroblast migration 
inhibiting factor (FIF), leukocyte migration inhibit- 
ing factor (LIF), and macrophage migration inhib- 
iting factor (MIF). These factors are all similar in 
function, inhibiting migration of their target cells 
specifically without inhibiting other functions of 
these cells. 
MIF has both stimulator and inhibitor activities, 
as MIF-mediated inhibition of monocyte/macro- 
phage migration mediated by MIF is also correlated 
with cutaneous delayed-type hypersensitivity 
(DTH). MIF is actually a group of peptides, ranging 
in molecular weight from 23 to 65 kD and in pI from 
2.4 to 5.6. These differences are not due to alter- 
ations in glycosylation, as tunicamycin does not 
convert one species into another (35). Characteris- 
tics of MIF include stability at 56°C; inhibition by 
L-fucose, L-rhamnose, and other 5-methylpentoses; 
and binding to a cell surface glycolipid receptor 
containing both fucose and sialic acid (35, 36). MIF 
can apparently be produced by either T or B cells 
alone, without the influence of the other subset of 
lymphocytes (37). Abnormalities in the production 
of MIF may play a role in disease symptomology, as 
lymphocytes from subjects with DiGeorge's syn- 
drome do not produce MIF (38). This also suggests 
that at least small numbers of T cells must be 
present with B cells for MIF production. 
LIF has an approximately molecular weight of 69 
kD and is produced by T and B cells following 
antigen or mitogen stimulation. LIF, similar to 
MIF, has both suppressive and stimulatory activi- 
ties, as LIF-mediated lymphocyte migration inhibi- 
tion occurs in concert with cellular hypersensitivity 
(37). LIF activity is inhibited by N-acetyl-D- 
glucosamine (39). LIF appears to function as both 
an esterase and a protease as demonstrated by its 
susceptibility to phenylmethylsulfonyl fluoride 
(PMSF), an irreversible enzyme inhibitor (40). 
Treatment of PMN with LIF elevates intracellular 
cGMP levels (41), while the production of LIF is 
inhibited by agents which increase intracetlular 
cAMP (42). 
FIF is an approximately 34-kD molecular weight 
factor that, as the name suggests, specifically inhib- 
its the migration of fibroblasts. FIF activity is 
disrupted by incubation at 80°C, and treatment with 
trypsin, chymotrypsin, and neuramididase, and is 
blocked by L-xylose, N-acetyl-D-glucosamine, 
D-mannose, L-rhamnose, and alpha-methyl-D- 
mannoside but not by L-fucose (39). A T-cell migra- 
tion inhibitory factor (TIF) has also been described 
(43). This factor is produced by cultures of PHA- 
treated T cells and inhibits migration of human T 
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lymphocytes. TIF activity has a molecular weight 
of 1 to 10 kD, an isoelectric point of 3. I, and can be 
separated from MIF by polyacrylamide gel electro- 
phoresis. TIF activity is resistant to trypsin, chy- 
motrypsin, and neruaminidase but, like LIF, is 
inhibited by PMSF. 
Soluble immune suppressor supernates (SISS) 
consists of two factors also produced by Con 
A-stimulated lymphocytes: SISS-T and SISS-B 
(36). SISS-T inhibits mitogen- and antigen- 
stimulated T-cell proliferation. Characteristics of 
SISS-T include a molecular weight of 30 to 45 kD; 
partial inactivation at 56°C, complete inactivation at 
80°C; being unaffected by exposure to acid or base; 
partial inhibition by N-acetyl-D-glucosamine 
(NAG); production by lymphocytes resistant to 
2000 R but not to 6000 R; and binding to the same 
cell surface receptors as the lectin wheat germ 
agglutinin (WGA) and Agaricus bisporus lectin (36). 
The latter finding is especially interesting, as WGA 
has been shown to bind to IL-2 receptors and 
interfere with maintaining high-affinity IL-2 binding 
sites on activated T cells, resulting in decreased 
peripheral blood mononuclear-cell (PBMC) prolif- 
eration (44). 
SISS-B has been clearly shown to differ from 
SISS-T. Functionally, SISS-B inhibits in vitro 
immunoglobulin (Ig) production by activated B 
cells. SISS-B has an apparent molecular weight of 
60 to 80 kD and is stable at pH 2.5 but is inactivated 
at 56°C. The activity of SISS-B is inhibited by 
L-rhamnose but not affected by NAG. SISS-B is 
produced by highly purified T cells (45). CTC- 
SISS-B, a suppressive factor produced by an IL-2- 
dependent suppressor T-cell line, appears to be 
similar or identical to SISS-B (46). CTC-SISS-B has 
been shown to suppress Ig production by directly 
interacting with activated B-cells, rather than via an 
indirect interaction with T cells or monocytes. 
Another suppressor factor produced by Con 
A-activated lymphocytes is the soluble immune 
suppressor factor (SISF) (47). SISF also binds to 
cells at the same surface receptor(s) recognized by 
WGA. A recent report states that patients with a 
variety of cancers show increased numbers of pe- 
ripheral blood lymphocyte (PBL) expressing sur- 
face receptors for WGA. These unique lympho- 
cytes decrease in number in patients who undergo 
curative resection of tumors or who respond to 
immunotherapy but not in patients who receive 
noncurative resection or who do not respond to 
immunotherapy, suggesting that SISF may play a 
role in the immunosuppression evidenced in many 
cancers (47). As SISF has not been well character- 
ized, it may be identical to other lymphokines such 
as SISS-T, which also binds to the cell surface 
WGA receptor. 
Inhibitor of DNA synthesis (IDS) is another in- 
hibitory lymphokine produced by Con A-stimulated 
lymphocytes. As the name suggests, IDS inhibits 
DNA synthesis by human peripheral blood lympho- 
cytes. IDS suppresses lymphocyte proliferation in 
response to antigens and lectins (48). Human IDS 
has a pI of 3.4 and a molecular weight of 20 kD; 
however, IDS is usually found in an 80-kD tet- 
rameric form. IDS' activity is inhibited by trypsin 
but is resistant to heat, RNAse, and DNAse. Peri- 
odate treatment also inhibits IDS-mediated sup- 
pression, suggesting that IDS is a glycoprotein and 
the carbohydrate moiety is necessary for suppres- 
sive functions (49). The mechanism of IDS- 
mediated suppression appears to be activation of 
adenylate cyclase activity in target cells (50). Sup- 
pression mediated by IDS is specific for DNA 
synthesis. IDS inhibits DNA synthesis in PHA- 
stimulated PBMC but has negligible effects on pro- 
tein and RNA synthesis in these cells, including 
production of IL-2, IL-2 receptor, and transferrin 
receptor. This further suggests that the mechanism 
of action of IDS is IL-2 independent (48). 
Pancre et al. (51, 52) have described a platelet 
activity-suppressive lymphokine (PASL) produced 
by Con A or antigenic stimulation of normal human 
CD8 ÷ lymphocytes. PASL is capable of suppress- 
ing IgE-dependent platelet cytotoxicity against 
Schistosoma mansoni larvae and production of ox- 
ygen metabolites by IgE-coated platelets. PASL is 
also produced by T lymphocytes from S. mansoni- 
infected humans when stimulated by S. mansoni 
antigens. This factor has a molecular weight of 15 to 
20 kD and a pI of 4.6. PASL is heat and acid stable 
and sensitive to trypsin and proteinase K but is not 
affected by neuraminidase treatment. Indomethacin 
does not affect PASL production. PASL appears to 
act directly on platelets, suggesting that it interacts 
with a platelet membrane surface receptor. PASL 
produced by humans is capable of inhibiting rat 
platelet cytotoxicity and rat PASL can suppress 
corresponding functions of humans. 
PWM-stimulated CD4 + cells have been reported 
to produce T-suppressor growth factor (TsGF) (53). 
This approximately 8-kD factor is necessary for the 
proliferation and differentiation of CD8 + lympho- 
cytes and functions by inducing IL-2 receptor 
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expression on CD8 + cells. CD8 ÷ cells stimulated by 
IL-2 plus T,GF demonstrate either the CD11 ÷ (sup- 
pressor effector) or the CD45R ÷ (suppressor in- 
ducer) phenotypes and are CD28- (cytotoxic T cell, 
To, phenotype). Prostaglandin E2 (PGE2) and IFN- 
gamma may also be necessary for differentiation of 
certain CD8 ÷ subsets. 
Another suppressive factor produced by stimu- 
lated human lymphocytes is T cell-specific suppres- 
sive activity (TSRA), a factor produced by T lym- 
phocytes stimulated by a soluble suppressor 
activating factor (SAF) (54). SAF is produced by a 
6-thioguanine-resistant mutant of the human T-cell 
line, CEM. TSRA is capable of suppressing mito- 
gen-activated T-cell proliferation, Tc generation, 
and PWM-stimulated PFC responses. SAF shows 
similar functional activities to TRSA but TRSA is 
50- to 500-fold more potent. Some evidence exists 
that TSRA is an activated form of SAF, paralleling 
the SIRS system (discussed below). Release of 
TSRA by SAF-stimulated lymphocytes appears to 
be partially inhibited in rheumatoid arthritis pa- 
tients (54). 
Soluble inhibitory factor (SIF) is a unique factor 
produced by T cells stimulated by tetanus toxoid or 
by MLR with cells from unrelated donors (55, 56). 
SIF appears to be produced by dividing T cells in 
proportion to their rate of division. SIF mediates 
inhibition of DNA synthesis and proliferation of 
PHA-stimulated PBL as measured by decreased 
3H-thymidine uptake, as well as inhibition of Ab 
production and PFC responses (55, 56) and inhibi- 
tion of 3H-thymidine uptake in the MLR (57). 
Characterization of SIF has revealed that this factor 
has two components, a carrier protein and a polar 
lipid. Immunosuppression is mediated by the lipid 
moiety, which is termed lipid suppressor substance 
(LSS). LSS and the protein are apparently bound 
by hydrophobic interactions, and are separated by 
dialysis against hypotonic solutions. LSS activity is 
stable at 56°C for 30 min but is destroyed by 70°C 
for 15 min. LSS is a polar lipid, possibly a glycolipid 
containing an amine group. However, LSS does not 
appear to be identical to common gangliosides (56). 
The protein moiety, which does not mediate medi- 
ate immunosuppression, has a molecular weight 
between 100 and 150 kD (57). 
Intact SIF activates a suppressor-cell population 
capable of inhibiting antigen- and mitogen-induced 
thymidine incorporation. These suppressor cells are 
not affected by the DNA synthesis inhibitor, mito- 
mycin C, indicating that their suppressor function 
does not require DNA synthesis. LSS by itself, 
however, does not appear to be capable of suppres- 
sor-cell induction. LSS may function by altering 
lymphocyte membrane function or fluidity (57). 
SIF has also been identified in normal human sera 
and found to be present at very high concentrations 
in serum from a patient with an unusual cutaneous 
lymphoma (57). SIF is also produced by cultures of 
multinucleated giant cells obtained from the villous 
surfaces of normal human placentae (58). 
One of the most extensively describeA suuppres- 
sor factors produced by stimulated lymphocytes is 
the soluble immune response suppressor (SIRS). 
Information on SIRS, both published and unpub- 
lished, has recently been reviewed by Aune (59). 
Much of the work on SIRS has been performed in 
the murine system, although recent work has ex- 
tended some of these observations to human immu- 
nology. SIRS is produced in a precursor form by 
Con A-stimulated murine Lyt 1-2 + T cells. This 
precursor is oxidized to the active (or more active) 
state by macrophages. To mediate suppression, 
SIRS-containing supernates must be added at the 
initiation of cell culture; however, SIRS-containing 
supernates cocultured with macrophages (to pro- 
duce the oxidized form of SIRS) are capable of 
suppressing lymphoid cells when added several 
days after the start of culture (60). 
SIRS is capable of suppressing primary and sec- 
ondary IgM and IgG responses in vitro to T cell- 
dependent and -independent antigens, DNA synthe- 
sis responses of lymphocytes to mitogens and 
alloantigens, and DNA synthesis and cell division 
by certain tumor-cell lines (60). SIRS-mediated sup- 
pression is inhibited by various compounds includ- 
ing catalase, 2-mercaptoethanol (2-ME), and perox- 
idase substrates. It is thought that these compounds 
inhibit the oxidation of the SIRS precursor by 
macrophages (60). 
SIRS has undergone partial biochemical charac- 
terization. The molecular weight of murine SIRS 
was initially determined to be 45 to 55 kD (60). 
Later work with a murine SIRS-producing hybrid- 
oma yielded a factor with a molecular weight of 21.5 
kDa that decreased to a molecular weight of 10 to 12 
kD in high-ionic strength buffers (61). Three iso- 
forms of murine SIRS have been described, with pI 
values of 5.0, 6.0, and 7.0 (62). 
Recently, a murine SIRS has been partially se- 
quenced. Antisera produced against a peptide con- 
sisting of the initial 21 N-terminal amino acids of 
SIRS can block suppressive activity mediated by 
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intact SIRS (63). Two mRNAs have been isolated 
which produce SIRS activity in a cell-flee transla- 
tion system. By velocity sedimentation, one mRNA 
is 21 to 22 S, while the other is 25 S. The former 
produces a product of molecular weight 7 to 8 kD, 
while the latter produced two products: one of 13 to 
14 kD and one of 7 to 8 kD. Both products had 
SIRS-like activity, and this activity was blocked by 
inhibitors of SIRS (64). The basis for the different 
apparent molecular weights of SIRS is unknown. 
Human SIRS had been previously described to 
have a molecular weight of approximately 130 kD 
(65); however, a later report indicated that the 
molecular weight of human SIRS in high-ionic 
strength and low-pH buffers was 15 kD (66). Human 
SIRS has a pI of 7.0 (59) and is inactivated at pH 2 
but not pH 4 (65). 
The mechanism of action of SIRS is under inves- 
tigation. In PFC assays, SIRS does not appear to 
inhibit Ig synthesis but, rather, interferes with Ig 
processing and/or secretion (66). It has been sug- 
gested that SIRS mediates this immunosuppression 
by causing oxidation of intracellular low molecular 
weight thiols and protein sulthydryls (59). One 
target for this oxidation is tubulin; SIRS is capable 
of inhibiting assembly of microtubule protein in a 
log concentration-dependent manner (67). 
IFN-associated immunosuppression may actually 
be mediated by SIRS. Murine IFN-beta activates a 
subset of suppressor lymphocytes (Lyt 1-2 +) that 
suppress plaque-forming cell (PFC) responses to 
sheep red blood cells (SRBC). This lymphocyte 
subset, when activated by IFN-beta or Con A, 
produces supernates which show many properties 
similar to SIRS (60). 
A similar system has been described in humans 
for the PFC response mediated by PWM-stimulated 
PBMC. This response can be suppressed by CD8 ÷ 
lymphocytes activated by Con A, IFN-alpha A, or 
IFN-garnma. Suppression mediated by these cells 
or by their supernates can be blocked by inhibitors 
of SIRS activity, including levamisole, catalase, 
2-ME, and ascorbic acid. This suppressive activity 
showed kinetics similar to those described for mu- 
rine SIRS (65). Kaufman et  al. (68) also reported 
that supernates from Con A-treated human lympho- 
cytes are capable of suppressing allogeneic and 
syngeneic MLR without causing cytotoxicity. This 
suppression was described as being "SIRS-like," 
although the suppressive activity was not further 
characterized. 
SIRS may al~o play a role in disease states. It has 
been reported that SIRS levels are elevated in 
schistosomiasis and in the nephrotic syndrome (59). 
Whether this elevation is a cause or a symptom of 
these states is unknown. 
Warfington (69) described a factor similar to 
SIRS produced by con A-activated human T cells, 
called T cell-suppressor factor (T-SF). T-SF in- 
duces macrophages to produce macrophage- 
derived suppressor factor (macrophage-SF) in the 
absence of any de novo protein synthesis. Both of 
these factors can suppress polyclonal B cell- 
activated Ig production without affecting B- or 
T-cell proliferation and can mediate this suppres- 
sion in the absence of T-ceUs. T-SF activity is 
inhibited by 2-ME and L-rhamnose. While the ac- 
tivity of macrophage-SF is inhibited by L-rhamnose, 
only its production appears to be inhibited by 
2-ME. T-SF must be added at the start of culture to 
mediate suppression, while macrophage-SF can be 
added later. T-SF has a molecular weight of approx- 
imately 20 kD, while macrophage-SF appears to be 
a complex with molecular weight >110 kD that 
dissociates into a 20-kD form in high-ionic strength 
buffers (69). 
Many properties of T-SF and macrophage-SF 
suggest that these molecules are identical to SIRS. 
However, there are some major differences in their 
actions. SIRS suppresses cell replication, while 
T-SF and macrophage-SF do not. T-SF cannot be 
activated to form macrophage-SF by peroxide, 
while SIRS can be so activated (69). Whether these 
two factors are identical to SIRS has yet to be 
determined. 
Cytokine synthesis inhibitory factor (CSIF), a 
recently reported lymphokine now designated as 
IL-10, is also produced by Con A-stimulated T cells 
(70). Murine IL-10 is produced by one class of 
long-term mouse T-cell clones, TH2 clones, and 
inhibits many of the functions of another class of 
clones, Tnl .  This includes inhibition of the produc- 
tion of IFN-gamma and partial inhibition of the 
production of other cytokines (70). IL-10 has no 
suppressive effects on cytokine production by TH2 
clones and does not affect viability or proliferation 
of THI clones (71). Inhibition of IFN-gamma pro- 
duction is due to inhibition of mRNA synthesis and 
is not due to alterations in IFN-gamma secretion 
(71). Inhibition of other cytokines produced by THI 
clones, including IL-2, lymphotoxin/tumor necrosis 
factor (LT/TNF), IL-3, and granulocyte/macro- 
phage colony-stimulating factor (GM-CSF), is spo- 
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radic; their synthesis is inhibited only in some 
instances (71). 
IL-10 is not capable of suppressing early cytokine 
synthesis. Thus it is not effective during the first 8.5 
hr following stimulation of clones of THI cells; only 
synthesis after this period is suppressed. Further, 
IL-10-mediated suppression is seen only in the 
presence of antigen-presenting cells (APC). One 
hypothesis is that IL-10 is modified in order to 
mediate suppression or IL-10 induces the synthesis 
of a second lymphokine which mediates suppres- 
sion (71). This could be similar to the mechanism of 
action of SIRS, described above, where the initial 
"prolymphokine" is modified by macrophages to 
form a more active moiety. 
IL-10 may also be produced in smaller amounts 
by unstimulated TH2 clones, but reports discussing 
this are contradictory (70). DNA coding IL-10 has 
recently been sequenced and shown to have homol- 
ogy with the Epstein-Barr virus gene BCRFI (70). 
Other suppressive activities yet to be fully char- 
acterized, but which may be similar or identical to 
factors described above, include a pair of suppres- 
sor factors, SFR and SFNR, produced by allosen- 
sitized cells (72); a factor produced by PWM- 
s t imula ted  suppres so r  T cells capable of 
suppressing autologous and allogeneic IgG, IgA, 
and IgM synthesis (73); and a factor produced by 
PWM and IgG immune complex stimulated T lym- 
phocytes bearing receptors for IgG (T c cells) that 
suppresses PWM-induced B-cell differentiation 
(74). 
SUPPRESSIVE LYMPHOKINES PRODUCED BY 
UNSTIMULATED LYMPHOCYTES 
A small number of factors have been described 
that are produced by unstimulated lymphocytes. 
The term "unstimulated" is somewhat of a misno- 
mer, as even lymphocytes in isolation are con- 
stantly being exposed to autologous HLA antigens, 
locally released mediators, and other endogenous 
molecules. Hence, unstimutated refers here to the 
lack of addition of any exogenous stimulatory mol- 
ecules. As noted above, IL-10 may be produced in 
the absence of any stimulation (70). Small amounts 
of SIF may also be produced by unstimulated T 
cells (65). Mortari and Singhal (75) have described a 
factor produced constitutively by a suppressor- 
enriched population of normal human bone marrow 
cells called bone marrow-derived suppressor factor 
(BDSF). BDSF suppresses in vitro primary anti- 
body responses and lectin-induced lymphocyte pro- 
liferation. BDSF has a molecular weight less than 
1.5 kD and contains a lipid moiety, but its produc- 
tion is indomethacin resistant. The cell type respon- 
sible for the production of BDSF is HNK-t ÷, but it 
does not bear surface markers of T or B cells or 
macrophages. 
Lederman et al. (76) have also described a factor 
produced by unstimulated lymphocytes called im- 
mune response suppressor factor (IRSF). This fac- 
tor is produced by a nonadherent cell population 
after 4 hr of culture in vitro. IRSF does not affect 
cell viability, and its release is not inhibited by 
indomethacin. IRSF is heat stable and is partially 
dialyzable through 12-kD exclusion size membrane. 
No further characterization of this factor has been 
performed, and its relation to other factors, includ- 
ing SSF (discussed below) is unknown. 
Soluble receptors for Fc portions of IgG (FcR) 
have been reported as being released from unstim- 
ulated human PBL. Although not commonly 
thought of as lymphokines, FcR fulfill the definition 
by being non-Ab, immunoregulatory molecules pro- 
duced by lymphocytes. FcR are capable of inhibit- 
ing the differentiation of PWM- or Nocardia opaca- 
stimulated peripheral B cells into Ig-secreting 
plasma cells without affecting cell viability or 3H- 
thymidine incorporation (77). Inhibition is dose 
dependent. Human FcR are thought to be analogues 
of murine immunoglobulin binding factors (IBF), 
glycoproteins which bind Fc portions of IgG and 
suppress the PFC response to SRBC (78) (79). 
Work in our laboratory has focused on the sup- 
pressive lymphokine soluble suppressor factor 
(SSF). SSF is lymphokine produced by unstimu- 
lated PBL in serum-free medium (80). SSF induc- 
tion is apparently a consequence of the autologous 
mixed lymphocyte reaction, as it is produced by 
neither T cells nor B cells alone. However, adher- 
ent cells are not required for its production. SSF is 
generated only in serum-free medium, as the pres- 
ence of serum inhibits its production. Biological 
actions of SSF include suppression of polyctonal 
B-cell activation, proliferative responses of normal 
PBL in responses to mitogen or alloantigens, and 
natural killer (NK) and antibody-dependent cellular 
cytotoxicity (ADCC) (81, 82). 
The mechanism of SSF-mediated suppression is 
uncertain but is not due to a cytotoxic effect (81). 
Binding of SSF to cell surfaces appears to involve a 
carbohydrate moiety, as SSF-mediated suppression 
of NK cytotoxicity can be inhibited in a dose- 
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dependent manner by L-fucose (Fuc) or D-galactose 
(Gal) (83). This inhibition appears to be due to 
binding of SSF to the monosaccharide, rather than 
the monosaccharide blocking a site on the cell 
surface. For the inhibition of SSF-mediated sup- 
pression, monosaccharides must be present within 
24 hr following the addition of SSF to effector-cell 
cultures; after 24 hr, the addition of monosaccha- 
rides does not affect suppression. 
Suppression mediated by SSF may be limited to 
preventing stimulation of lymphocytes rather than 
suppressing lymphocytes already stimulated. In the 
one-way MLR, SSF was capable of mediating sup- 
pression when added during the first 4 days of 
culture but not when added on day 5 or 6 (81). This 
suggests that only early events in the MLR can be 
suppressed by SSF. 
Investigations into the interaction of SSF with 
other lymphokines has begun. The immune modu- 
lator IFN-alpha is capable of partially reversing 
SSF-mediated suppression of NK cytotoxicity (82). 
However, recent experiments indicate that IFN can 
also stimulate production of SSF activity (84). This 
paradoxical activity of IFN may serve as a feedback 
inhibition mechanism within the AMLR, preventing 
overstimulation and possible subsequent autoim- 
mune reactions. 1L-2 is also capable of reversing 
SSF-mediated suppression. In contrast to the ac- 
tions of IFN, however, IL-2 appears to be able to 
suppress production of SSF (80). 
The biochemical characterization of SSF has 
been partially completed. SSF activity appears in 
the fraction <20 kD when separated by membrane 
ultrafiltration (82). On gel filtration, activity appears 
in two peaks: one between the 25-kD and the 
13.7-kD markers and the second below the 13.7-kD 
marker. The higher molecular weight peak showed 
a majority of the biological activity (82). SSF is heat 
stable at 56°C for 30 min, but loss of suppressor 
activity occurs after incubation at 70°C for 30 min 
(81). SSF is sensitive to the proteolytic enzymes 
trypsin and chymotrypsin, suggesting that it is, at 
least in part, a polypeptide (80). Acidic conditions 
slightly decrease SSF's activity, while its activity is 
totally abrogated following treatment at basic pH 
(80). SSF also appears to be glycosylated, as SSF 
activity is specifically removed from SSF-contain- 
ing supernates by lentil lectin (from Lens culinaris). 
SSF activity can be recovered following elution of 
lectin-bound material by 0.1 M mannose (unpub- 
lished observation). 
SSF has recently been isolated in our laboratory 
(85). Following controlled-pore glass (CPG) chro- 
matography, SSF activity is found in a high-pH (0.1 
M Tris, pH 8.5) elution. The suppressive activity in 
this elution has a molecular weight less than 30 kD, 
is sensitive to proteases, and is inhibited by anti- 
SSF monoclonal antibody (mAb), all identical to 
SSF activity in crude supernates. 
On polyacrylamide gel electrophoresis, this CPG 
elution reveals one major band with a molecular 
weight of approximately 20 kD. Electroelution of 
this band produces material with SSF activity. This 
activity is also inhibited by anti-SSF mAb (85). 
Isoelectric focusing (1EF) gel electrophoresis of the 
polyacrylamide gel eluate reveals two bands, at pI 
values of 8.2 and 8.4. Upon electroeluting, the 
eluates from either band are capable of mediating 
SSF-like suppression, and this suppression is inhib- 
ited by anti-SSF mAb. We therefore conclude that 
this purified material is SSF. The two pI values may 
be due to alteration caused during the harsh purifi- 
cation process or to native SSF having two distinct 
isoforms. 
SSF does not appear to be identical to other 
previously isolated soluble mediators. Antibodies 
to 1FN-gamma, 1L-1, IL-2, TGF-beta, platelet fac- 
tor 4 (PF4), and connective tissue activating peptide 
Ill (CTAP-I11) do not affect SSF-mediated suppres- 
sion of NK cytotoxicity (85). Antibody to tumor 
necrosis factor (TNF) does partially inhibit SSF- 
mediated suppression; however, even at a very high 
concentration (100 U/ml), TNF is incapable of me- 
diating suppression of NK cytotoxicity (85). We 
therefore conclude that SSF and TNF are distinct 
moieties but may well share sequence homology to 
some degree. 
The specific lymphocyte subpopulation responsi- 
ble for the production of SSF has not yet been 
completely determined; however, preliminary stud- 
ies indicate that the cell producing SSF is a CD3 ÷, 
CD4-, CD8 +, HNK-1 ÷ lymphocyte (unpublished 
observation). Production of SSF is unaffected by 
preirradiation of lymphocytes with up to 2000 rads 
(80), suggesting that SSF may be produced by a 
unique radioresistant subset of lymphocytes of the 
suppressor phenotype. 
Nair et at. (86) have described a suppressor factor 
produced by histamine-stimulated PBL (histamine- 
induced soluble suppressor factor, HISSF). Like 
SSF, this HISSF is capable of suppressing NK 
cytotoxicity, and this suppression can be partially 
reversed by IFN-alpha or IL-2. This factor shows at 
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least partial sequence homology to SSF, as a mAb 
generated against HISSF is capable of neutralizing 
the activity of SSF (unpublished observation). Thus 
it remains to be determined if histamine can up- 
regulate SSF production/activity or whether SSF 
and HISSF are two distinct moieties. 
CONCLUSION 
Our understanding of the role of lymphokines in 
immunosuppression has greatly increased over the 
past few years. It is now evident that suppressive 
lymphokines, or lymphokines with certain suppres- 
sive functions, are vital for the homeostasis of the 
immune system and are probably involved in the 
etiology and pathogenesis of a number of disease 
states. Unfortunately, there has been little charac- 
terization of most of these lymphokines beyond 
initial descriptions. To further our understanding of 
the complex interactions within immune responses, 
in both in normal states and diseased or altered 
states, a more rigorous examination of various 
suppressive activities is necessary. Similarities or 
identities between different mediators can then be 
determined, and a more integrated picture of im- 
mune regulation may be revealed. 
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